Introduction
============

Although the immune system generally recognizes abnormal proteins on tumor cells as tumor antigens, spontaneous immune responses are too weak to suppress tumor growth. To overcome this problem, a variety of adjuvants, including toll-like receptor (TLR) ligands, are investigated to potentiate antitumor immunity. The bacillus Calmette-Guérin (BCG), historically known for its effective adjuvant properties, is often used in the treatment of cancer patients ([@b1-or-37-02-0684]).

The innate immune system recognizes pathogen-associated molecular patterns expressed on microorganisms through corresponding TLRs, and the activation of innate immunity by TLRs produces proinflammatory cytokines such as interleukin (IL)-6 and IL-12, leading to the subsequent induction of adaptive immune responses ([@b2-or-37-02-0684],[@b3-or-37-02-0684]). IL-12 is produced by macrophages (MΦ) and dendritic cells (DC) and dictates the differentiation of CD4 Th1 cells, which produce interferon (IFN)-γ and activate natural killer (NK) cells and cytotoxic CD8 T cells ([@b4-or-37-02-0684]). IFN-γ plays an important role in the prevention of primary tumor development and intracellular pathogen invasion ([@b5-or-37-02-0684]--[@b7-or-37-02-0684]). Among the different TLR ligands, lipopolysaccharide (LPS) from gram-negative bacteria exhibits antitumor activity in addition to marked toxicity ([@b8-or-37-02-0684]). The study of the bioactivity of LPS from various species revealed that LPS prepared from *Bordetella pertussis* and a synthetic analog of the LPS lipid A subunit are less toxic than *E. coli* LPS, and display antitumor effects ([@b9-or-37-02-0684],[@b10-or-37-02-0684]).

Recent studies have revealed that IL-23/IL-17 signaling plays an important role in tumorigenesis and metastasis in humans and in mice ([@b11-or-37-02-0684]--[@b16-or-37-02-0684]). IL-17 is primarily produced by T cells and acts on tumor cells and tumor-associated stromal cells to induce angiogenesis and the production of IL-6, IL-8, and matrix metalloproteinases. IL-23 is produced by Mϕ/DC and facilitates the expansion and survival of IL-17-producing CD4 T (Th17) cells and therefore, the production of IL-17 ([@b17-or-37-02-0684],[@b18-or-37-02-0684]). Moreover, it has become evident that a combination of IL-6 and transforming growth factor (TGF)-β induces Th17 differentiation from naive T cells ([@b19-or-37-02-0684],[@b20-or-37-02-0684]). Since Mϕ/DC produces both antitumor (IL-12) and tumor-promoting (IL-6/IL-23) cytokines upon stimulation with TLR ligands ([@b21-or-37-02-0684],[@b22-or-37-02-0684]), the regulation of this balance is critical for TLR-based cancer immunotherapy ([@b17-or-37-02-0684],[@b18-or-37-02-0684]). Moreover, IL-17 stimulates tumor cells and tumor-surrounding cells to induce IL-6 expression, which in turn leads to the activation of signal transducer and activator of transcription 3 (STAT3) ([@b16-or-37-02-0684],[@b23-or-37-02-0684]). STAT3 is linked to numerous oncogenic signaling pathways and is constitutively activated both in tumor cells and in immune cells under tumor microenvironment-like conditions. Thus, ideal candidate molecules for tumor immunotherapy are TLR-based immunomodulators that do not induce or partially induce IL-6/IL-23.

While exploring TLR4 responsiveness of the material extracted from algae and cyanobacteria ([@b24-or-37-02-0684]), we found that LPS phenol-water extracts from *Spirulina (Arthrospira)* were able to induce IL-12. Noteworthy, *Spirulina* LPS showed a much lower *in vitro* induction of IL-6 and IL-23 by Mϕ/DC than *E. coli* LPS. *Spirulina* is a gram-negative, oxygenic, photosynthetic, filamentous cyanobacterium (blue-green alga), and since the Aztec civilization in Mexico, it has been widely used as a nutritional and therapeutic supplement ([@b25-or-37-02-0684]). *Spirulina* LPS is reported to be less toxic compared to LPS from *Salmonella abortus* ([@b26-or-37-02-0684]), but its effects on cytokine production or antitumor activities have not been studied extensively. Thus, it would be very interesting to study how *Spirulina* LPS affects tumor growth and *in vivo* production of inflammatory cytokines.

Although most experiments examined the *in vitro* production of IL-17-associated inflammatory cytokines thus far, the expression patterns of these cytokines in tumor host tissue remain to be established. We report here that *Spirulina* LPS did not induce or only partially induced IL-6 and IL-23 and efficiently suppressed the growth of hepatocellular carcinoma MH134 in a TLR4-dependent manner, by reducing the serum levels of IL-17 and IL-23, while increasing those of IFN-γ. Interestingly, anti-IL-17 monoclonal antibodies (mAb) clearly suppressed tumor growth as efficiently as *Spirulina* LPS. Furthermore, *Spirulina* LPS was quite effective in inhibiting spontaneous development of mammary tumors in an oncogene transgenic mouse model.

Materials and methods
=====================

### Mice and tumor cells

Female C3H/HeN and C3H/HeJ mice were purchased from CLEA Japan Inc. (Tokyo, Japan). DO11.10 transgenic mice for αβ T-cell receptor (TCR) recognizing ovalbumin (OVA) in the context of I-A^d^ and transgenic mice carrying an activated rat HER-2/*neu* oncogene driven by a mouse mammary tumor virus promoter (HER-2/*neu* mice) were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and Charles River Laboratories (Cambridge, MA, USA), respectively. All mice were maintained in a pathogen-free environment, and experiments were performed following the ethical guidelines of Kochi Medical School and Osaka Ohtani University. The mouse tumor MH134 (hepatocellular carcinoma; kindly provided by Dr T. Kudo, Tohoku University, Sendai, Japan) and YAC-1 (T-cell lymphoma) cell lines were maintained in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) with 10% heat-inactivated fetal calf serum (FCS, HyClone Laboratories, Logan, UT, USA), 5×10^−5^ M 2-mercaptoethanol (2-ME), and 50 µg/ml gentamicin (Sigma-Aldrich).

### Reagents

LPS from *Escherichia coli (E. coli)* 0111:B4 was purchased from Difco (Detroit, MI, USA). Anti-IFN-γ mAb (R4-6A2, rat IgG1; no. MM701), anti-IL-17 mAb (50104, rat IgG2a; no. MAB421), anti-CD8 mAb (53--6.7, rat IgG2a; no. 100735), and rat IgG were obtained from Endogen (Rockford, IL, USA), R&D Systems (Minneapolis, MN, USA), BioLegend (San Diego, CA, USA), and Sigma-Aldrich, respectively. Anti-CD4 mAb (GK1.5, rat IgG2b) was kindly provided by Dr F.W. Fitch (University of Chicago, Chicago, IL, USA).

### Preparation of LPS from Spirulina pacifica

*S. pacifica* was a generous gift from Dr Genrald Cysewski (Cyanotech Corporation, Kailua-Kona, Hawaii, USA) and Mr. Nobuyuki Miyaji (Toyo Koso Kagaku Co., Ltd., Chiba, Japan). *S. pacifica* has been selected from a strain of edible *S. platensis* in 1984 and its enzyme expression profile differs from that of the parental strain. LPS was prepared from *S. pacifica* freeze-dried cells as previously described ([@b27-or-37-02-0684]). Briefly, cells were washed with acetone, suspended in distilled water, and then extracted by addition of 90% phenol-water and vigorous agitation at 68°C. The crude preparation was dialyzed to remove phenol and residual freeze-dried cells. The sample was dissolved in water, and the insoluble material was eliminated by centrifugation, followed by ultracentrifugation at 100,000 × g. The molecular mass of the LPS sample was estimated between approximately 1,000 and 20,000 Da by electrophoresis and mass spectral analysis.

### Tumor growth in vivo

Tumor growth was measured 3 times per week after intradermal (i.d.) injection of 1×10^6^ MH134 cells in the back of C3H/HeN or C3H/HeJ mice. The tumor volume was calculated using the following formula: Volume (mm^3^) = width^2^ × length/2. In some experimental settings, *Spirulina* LPS or *E. coli* LPS in saline solution was injected intraperitoneally (i.p.) every week starting 6 days after tumor inoculation. To deplete the T-cell subsets, mice injected with MH134 tumor cells on day 0 were injected i.p. with rat IgG, anti-CD4, or anti-CD8 mAb (150 µg/mouse on days, −1, 0, +3) as previously described ([@b28-or-37-02-0684]). T-cell depletion was confirmed to be \>95% by fluorescence-activated cell sorting (FACS).

### Surgical tumor resection and rechallenge

MH134 tumors were surgically removed 3 weeks after tumor inoculation. Mice were re-challenged i.d. with 1.5×10^6^ MH134 cells of the same tumor as previously described ([@b29-or-37-02-0684]).

### Immunohistochemistry

MH134 tumors taken from C3H/HeN mice treated with saline solution or *Spirulina* LPS 22 days after tumor implantation were embedded in O.C.T. compound (Sakura Finetec USA, Inc., Torrance, CA, USA) and frozen. Frozen tumors were sectioned and stained with anti-CD4 (RM4-5, rat IgG2a, no. 100520, BioLegend) or anti-CD8 (53--6.7) antibodies using simple stain mouse MAX-PO \[F(ab)\'~2~ goat anti-rat Ig and peroxidase coupled to the amino acid polymer\] and 3,3′-diaminobenzidine according to the manufacturer\'s protocol (Nichirei-Biosciences Inc., Tokyo, Japan).

### Preparation of lymphoid cells

Mϕ/DC or CD4 T cell fractions were prepared from whole spleen cells by positive selection using a MACS cell separation system (Miltenyi Biotec, Auburn, CA, USA) according to manufacturer\'s instructions. Anti-CD4 and a mixture of anti-CD11b and anti-CD11c microbeads were used for the fractionation of CD4 T cells and Mϕ/DC, respectively. The purity was usually demonstrated to be \>90% by FACS.

### Culture of splenocytes from tumor-bearing mice

Whole splenocytes (5×10^6^/well) depleted of red blood cells were cultured in 10% FCS RPMI-1640 medium in 24-well culture plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA) at 37°C in a 5% CO~2~ humidified atmosphere. After 4 days of culture, supernatants were collected to assess cytokine levels by ELISA.

### In vitro IL-17 production

Whole spleen cells (8×10^5^/well) from OVA-specific TCR transgenic (DO11.10) mice were cultured in flat-bottomed 96-well plates (Costar Corning, NY, USA) in 10% FCS RPMI-1640 medium for 5 days. In some experiments, 2.8×10^5^ CD4 T cells, prepared from C3H/HeJ mice that had been immunized i.p. with 150 µg OVA and 5 mg Alum approximately 2 months earlier, were cultured with 1.2×10^5^ splenic Mϕ/DC cells from C3H/HeN or C3H/HeJ mice in the presence of 20 µg/ml OVA for 5 days. *Spirulina* or *E. coli* LPS was added at the initiation of the culture to evaluate its effect on IL-17 production. The levels of IL-17 in the culture supernatants were evaluated by ELISA.

### B cell proliferation

Whole spleen cells (8×10^5^/well) were cultured in flat-bottomed 96-well plates in 10% FCS RPMI-1640 medium in the presence or absence of graded doses of *Spirulina* LPS or *E. coli* LPS. Five days later, the cultured cells were collected and stained with FITC-conjugated anti-B220 mAb (RA3-6B2, rat IgG2a, no. 553088, BD Biosciences, San Jose, CA, USA). B220^+^ cells were counted as B cells using a FACSCalibur instrument (Becton Dickinson, San Jose, CA, USA).

### NK assay

Briefly, 2.5×10^6^ target cells were labeled with 25 µCi of ^51^Cr sodium chromate for 60 min at 37°C in 10% FCS RPMI-1640 medium. After washing, ^51^Cr-labeled target cells (1×10^4^) and effector cells were mixed in flat-bottomed 96-well plates at the indicated effector/target (E/T) ratio. After 4 h of incubation, the radioactivity in the cell-free supernatants was measured using a 1470 Automatic Gamma Counter (PerkinElmer, Waltham, MA, USA). Percentage-specific lysis for ^51^Cr release was calculated according to the following formula: % specific lysis = \[(experimental - spontaneous) release\] / \[(maximal - spontaneous) release\] ×100.

### ELISA for cytokine measurement

Cytokine levels in serum or culture supernatants were quantified by sandwich ELISA. The following pairs of capture and biotinylated detection rat anti-mouse mAbs were used: R4-6A2 (no. 551216) and XMG1.2 (no. 554410) for IFN-γ, TC11-18H10 (no. 555068) and TC11-8H4 (no. 555067) for IL-17, 9A5 (no. 554658) and C17.8 (no. 554476) for IL-12(p35/40), MP5-20F3 (no. 554400) and MP5-32C11 (no. 554402) for IL-6, and A75-2 (no. 555052) and A75-3 (no. 555053) for TGF-β1 (all were purchased from BD Biosciences). For IL-23(p19/40), rat anti-mouse IL-23p19 (G23-8, no. 14-7232-85, eBioscience, San Diego, CA, USA) and biotinylated anti-IL-12p40 (C17.8, BD Biosciences) were used. The ELISA assays were performed according to the manufacturer\'s instructions.

### Statistical analysis

Differences in mean values between groups were calculated using an unpaired two-tailed Student\'s t-test, Mann-Whitney U test, or Fischer\'s exact test. P-values of the Student\'s t tests are shown unless otherwise indicated.

Results
=======

### TLR4-dependent suppression of tumor growth by Spirulina LPS is mediated by CD4 and CD8 T cells

To examine the antitumor activities of *Spirulina* LPS in comparison with that of *E. coli* LPS, we inoculated hepatocellular carcinoma MH134 cells i.d. into syngeneic C3H/HeN and TLR4 mutant C3H/HeJ mice ([@b30-or-37-02-0684]), followed by i.p. administration of different doses of *Spirulina* LPS or *E. coli* LPS 6 days later. The injection with different doses of *Spirulina* LPS suppressed the tumor growth in C3H/HeN but not in C3H/HeJ mice, to the same degree as *E. coli* LPS treatment ([Fig. 1A](#f1-or-37-02-0684){ref-type="fig"}). This suggests that *Spirulina* LPS as well as *E. coli* LPS reduced tumor growth in a TLR4-dependent manner.

In order to assess the involvement of T cells in the *Spirulina* LPS-induced antitumor effect, we administered anti-CD4 and/or anti-CD8 mAbs to deplete the T-cell subsets before *Spirulina* LPS injection. While injection of both anti-CD4 and anti-CD8 mAbs completely abolished the antitumor activity of *Spirulina* LPS, anti-CD4 or anti-CD8 mAb alone did not result in a strong effect ([Fig. 1B](#f1-or-37-02-0684){ref-type="fig"}). In accordance with the results of the *in vivo* T-cell depletion, immunohistochemical examinations revealed the enhancement of infiltration of both CD4 and CD8 T cells in the tumor masses upon administration of *Spirulina* LPS ([Fig. 1C](#f1-or-37-02-0684){ref-type="fig"}). These results suggest that CD4 and CD8 T cells are both involved in the antitumor effect induced by *Spirulina* LPS.

### Spirulina and E. coli LPS differ in their ability to activate NK cells and induce secondary immune responses

To examine whether *Spirulina* LPS induces immunity against MH134 tumors, we reinoculated MH134 cells into C3H/HeN mice that had been implanted with an MH134 tumor and were treated with saline, *E. coli*, or *Spirulina* LPS, followed by surgical resection of primary tumors 5 days before the re-challenge. The growth rate of the reimplanted tumors reduced even in saline-treated mice, compared with that in untreated mice implanted with only new tumor cells without the first inoculum of MH134 tumor cells ([Fig. 2A](#f2-or-37-02-0684){ref-type="fig"}), implicating the induction of antitumor immunity without LPS administration when the primary tumor was removed. *Spirulina* LPS induced a stronger resistance to reimplanted MH134 tumors than saline ([Fig. 2A](#f2-or-37-02-0684){ref-type="fig"}). In contrast, the tumor growth rate in *E. coli* LPS-treated mice was comparable to that in saline-treated mice ([Fig. 2A](#f2-or-37-02-0684){ref-type="fig"}). These results suggest that while *Spirulina* LPS facilitated the generation of immunity against MH134 tumors, *E. coli* LPS did not enhance secondary antitumor immune response. Since *E. coli* LPS was effective in the prevention of primary tumor growth as shown in [Fig. 1A](#f1-or-37-02-0684){ref-type="fig"} and is known to exhibit antitumor activity partly through activation of NK cells, we evaluated the ability of *E. coli* and *Spirulina* LPS to activate NK cells. Indeed, spleen cells from C3H/HeN mice injected with *E. coli* LPS showed remarkable toxicity towards NK-sensitive YAC-1 cells and a weak but significant toxicity towards MH134 cells, whereas *Spirulina* LPS failed to activate NK cells ([Fig. 2B](#f2-or-37-02-0684){ref-type="fig"}). NK activation was not induced in C3H/HeJ mice, not even when *E. coli* LPS was administered ([Fig. 2B](#f2-or-37-02-0684){ref-type="fig"}). Thus, this result may explain why *E. coli* LPS elicited antitumor effects against the primary tumor, regardless of its failure to enhance adaptive immunity to tumors.

### Administration of Spirulina LPS to a tumor-bearing host downregulates serum levels of IL-17 and IL-23 but increases IFN-γ production by T cells through the TLR4 pathway

IFN-γ plays a crucial role in the prevention of tumor development ([@b6-or-37-02-0684]), whereas IL-17 and IL-23 are considered to promote tumor growth by inducing inflammation and by regulating the expansion/survival of Th17 cells, respectively ([@b11-or-37-02-0684],[@b14-or-37-02-0684]--[@b16-or-37-02-0684]). We measured serum levels of IFN-γ, IL-17, and IL-23 in tumor-bearing C3H/HeN and C3H/HeJ mice treated with saline, *E. coli*, or *Spirulina* LPS. *E. coli* and *Spirulina* LPS (100 µg) markedly increased serum IFN-γ levels in C3H/HeN mice with a peak response at days 7 and 14 after tumor inoculation, respectively ([Fig. 3A](#f3-or-37-02-0684){ref-type="fig"}). A low dose of *Spirulina* LPS (20 µg) induced slight but significant IFN-γ production from days 7 to 14. However, the serum levels of IFN-γ were not elevated in C3H/HeJ mice at any time, not even after injection of either LPS. The treatment with anti-CD4 mAb or a combination of anti-CD4 and anti-CD8 mAbs abrogated the increase in serum IFN-γ in C3H/HeN mice receiving *Spirulina* LPS, whereas anti-CD8 mAb alone slightly diminished the activity of *Spirulina* LPS to induce IFN-γ ([Fig. 3D](#f3-or-37-02-0684){ref-type="fig"}). On the other hand, serum levels of IL-17 and IL-23 in saline-treated C3H/HeN mice gradually increased during tumor progression and reached a maximum on day 21 ([Fig. 3B and C](#f3-or-37-02-0684){ref-type="fig"}). However, serum levels of IL-6 only showed an approximately 2-fold increase in saline-treated tumor-bearing mice even on day 21 as compared to non-treated mice (data not shown). Noteworthy, *Spirulina* LPS significantly reduced IL-17 and IL-23 levels, while *E. coli* LPS hardly suppressed IL-17 production on day 21 ([Fig. 3B and C](#f3-or-37-02-0684){ref-type="fig"}). On the contrary, *E. coli* LPS enhanced serum levels of IL-23 in tumor-bearing C3H/HeN mice on day 7 and 14. Taken together, these results support the notion that *Spirulina* LPS induces antitumor immune responses through the induction of IFN-γ mostly by CD4 T cells and suppressed serum levels of IL-17 and IL-23, whereas *E. coli* LPS exerts its antitumor effect primarily through activation of NK cells.

We have previously shown that antigen-presenting cells (APCs)-expressing tumor Ag and tumor-reactive T cells are both stimulated *in vivo* in tumor-bearing mice, and that *in vitro* culture of spleen cells from tumor-bearing mice at early stages leads to cytokine production without exogenous addition of tumor Ag as a result of the collaboration between antitumor T cells and APCs ([@b29-or-37-02-0684],[@b31-or-37-02-0684]). We tested whether *in vivo* treatment with *E. coli* or *Spirulina* LPS affects the *in vitro* production of IFN-γ by culturing spleen cells from MH134 tumor-bearing mice. *Spirulina* LPS clearly enhanced IFN-γ production in spleen cells of tumor-bearing C3H/HeN mice, whereas *E. coli* LPS was unable to upregulate IFN-γ production ([Fig. 3D](#f3-or-37-02-0684){ref-type="fig"}). These results implicate that *Spirulina* LPS enhances IFN-γ production through the generation of memory T cells.

### Spirulina LPS inhibits IL-17 production in an IFN-γ-independent manner through interaction with APCs expressing TLR4

Since *Spirulina* LPS reduced serum IL-17 levels in tumor-bearing mice while increasing IFN-γ levels and because IFN-γ negatively regulates the generation of Th17 cells ([@b32-or-37-02-0684],[@b33-or-37-02-0684]), we investigated whether IL-17 downregulation by *Spirulina* LPS occurs via inhibition of the induction of IL-17-producing cells by facilitating IFN-γ production, or alternatively by directly downregulating IL-17-producing cells. To address this question, spleen cells from OVA-specific TCR transgenic DO11.10 mice were stimulated by OVA with or without *E. coli* or *Spirulina* LPS and in the presence or absence of anti-IFN-γ mAb. *Spirulina* LPS significantly suppressed IL-17 production by DO11.10 spleen cells in a dose-dependent manner, regardless of the presence of anti-IFN-γ mAb. However, *E. coli* LPS augmented IL-17 production ([Fig. 4A](#f4-or-37-02-0684){ref-type="fig"}), possibly because of its ability to induce IL-6 ([Fig. 5A](#f5-or-37-02-0684){ref-type="fig"}). In addition, it is noteworthy that anti-IFN-γ mAb enhanced IL-17 production by DO11.10 spleen cells in response to OVA without the addition of either LPS ([Fig. 4A](#f4-or-37-02-0684){ref-type="fig"}), indicating that IFN-γ regulates IL-17-producing cells. Thus, *Spirulina* LPS suppresses the *in vivo* production of IL-17 with or without involvement of IFN-γ. Moreover, although *Spirulina* LPS inhibited IL-17 production when CD4 T cells from OVA-primed C3H/HeJ mice were co-cultured with C3H/HeN APCs in the presence of OVA, it failed to suppress IL-17 production when OVA-primed C3H/HeJ CD4 T cells were stimulated with OVA in the context of C3H/HeJ APCs ([Fig. 4B](#f4-or-37-02-0684){ref-type="fig"}). These results suggest that *Spirulina* LPS acted on APCs to inhibit the generation of Th17 cells in a TLR4-dependent manner.

### Anti-IL-17 mAb administration inhibits tumor development upon elevated IFN-γ production

Thus far, our results are consistent with the notion that the antitumor effect of *Spirulina* LPS is caused by the downregulation of IL-17 production. To examine whether neutralization of IL-17 by anti-IL-17 mAb would result in a reduction of tumor growth in mice in the absence of *Spirulina* LPS, we injected anti-IL-17 or anti-IFN-γ mAb into C3H/HeN mice 1 day before and 4 days after MH134 tumor implantation, and monitored tumor development. As expected, anti-IL-17 mAb markedly suppressed tumor growth compared to control rat IgG antibodies, whereas anti-IFN-γ mAb slightly enhanced tumor development ([Fig. 4C](#f4-or-37-02-0684){ref-type="fig"}). Importantly, mice receiving anti-IL-17 mAb exhibited high levels of serum IFN-γ ([Fig. 4D](#f4-or-37-02-0684){ref-type="fig"}). In addition, *in vitro* culture of spleen cells from tumor-bearing mice treated with anti-IL-17 mAb resulted in the production of large amounts of IFN-γ ([Fig. 4D](#f4-or-37-02-0684){ref-type="fig"}). These results indicate that IL-17 provides an environment suitable for tumor growth partly by inhibiting the generation of IFN-γ-producing T cells.

### Spirulina LPS reduces or abrogates IL-6 and IL-23 production in vivo, but augments T cell-dependent IL-12 induction

It was recently reported that IL-17 is mainly produced by Th17 cells, and that both IL-6 and TGF-β are indispensable for the generation of Th17 cells ([@b20-or-37-02-0684]). To test the ability of *Spirulina* LPS to induce IL-6 and TGF-β, normal C3H/HeN and C3H/HeJ mice were injected i.p. with *E. coli* or *Spirulina* LPS and serum cytokine levels were measured 4 h later. C3H/HeN mice produced high levels of IL-6 in response to *E. coli* LPS, but showed only a small response upon stimulation with *Spirulina* LPS ([Fig. 5A](#f5-or-37-02-0684){ref-type="fig"}). Contrary to IL-6, the substantial TGF-β levels present in serum of untreated groups of both strains were not significantly elevated when stimulated with *E. coli* LPS ([Fig. 5A](#f5-or-37-02-0684){ref-type="fig"}). However, *Spirulina* LPS slightly reduced TGF-β levels, but only in C3H/HeN mice ([Fig. 5A](#f5-or-37-02-0684){ref-type="fig"}). Noteworthy, *E. coli* LPS elicited a considerable increase in IL-23 levels, only in C3H/HeN mice, while *Spirulina* LPS showed almost no induction of IL-23 even in C3H/HeN mice ([Fig. 5A](#f5-or-37-02-0684){ref-type="fig"}). Thus, *Spirulina* LPS seems to be inferior to *E. coli* LPS in terms of stimulating immune cells. The possibility that *Spirulina* LPS has a general defect in the stimulation of immune system was excluded, because both *E. coli* and *Spirulina* LPS induced B cell proliferation in a dose-dependent manner ([Fig. 5B](#f5-or-37-02-0684){ref-type="fig"}).

Since IL-12 and IFN-γ are known to play a crucial role in the differentiation of IFN-γ-producing Th1 cells ([@b4-or-37-02-0684]), we measured the serum levels of IL-12 in tumor-bearing mice that were treated with saline, *E. coli*, or *Spirulina* LPS. *Spirulina* LPS augmented IL-12 production more than *E. coli* LPS. In contrast to a transient increase of IL-12 by *E. coli* LPS, the enhanced IL-12 production by *Spirulina* LPS was still observed after 14 days ([Fig. 5C](#f5-or-37-02-0684){ref-type="fig"}). Of note, these high IL-12 serum levels on day 14 decreased when C3H/HeN mice were injected with anti-CD4, but not anti-CD8 mAb ([Fig. 5D](#f5-or-37-02-0684){ref-type="fig"}), implicating CD4 T cell-dependent IL-12 production. Taken together, these findings support the notion that *Spirulina* LPS facilitates the priming of CD4 T cells with tumor cells and the subsequent CD4 T cell-dependent activation of APCs, leading to IL-12 production, which in turn induces IFN-γ-producing T cells.

### Spirulina LPS attenuates the spontaneous development of mammary tumors

We finally examined whether *Spirulina* LPS is also effective in suppressing the spontaneous development of mammary tumors in female transgenic mice carrying the activated HER-2/*neu* oncogene. HER-2/*neu* transgenic mice display apparent hyperplasia in the mammary glands at 10 weeks of age and develop palpable mammary tumors around 24 weeks ([@b28-or-37-02-0684]). Female HER-2/*neu* mice were injected with *Spirulina* LPS or PBS once per week between 120 and 240 days after birth. *Spirulina* LPS delayed the appearance of tumors and significantly reduced both tumor incidence and growth ([Fig. 6](#f6-or-37-02-0684){ref-type="fig"}).

Discussion
==========

The IL-12/IFN-γ pathway is crucial for antitumor immunity by inducing IFN-γ-producing CD4 and CD8 T cells ([@b4-or-37-02-0684],[@b6-or-37-02-0684],[@b7-or-37-02-0684],[@b34-or-37-02-0684]). In this context, various adjuvants including microbial products are explored to potentiate antitumor immunity. On the other hand, IL-23/IL-17 signaling plays an important role in tumorigenesis and metastasis in humans and mice by inducing angiogenesis and IL-6, IL-8, and matrix metalloproteinase expression ([@b11-or-37-02-0684]--[@b17-or-37-02-0684]). Since most adjuvants induce IL-6, which is indispensable for Th17 differentiation, adjuvants that do not induce or slightly induce IL-6 are desired for tumor immunotherapy. The present study demonstrates that *Spirulina* LPS is a very poor inducer of IL-6 and IL-23 and that it elicits strong antitumor immunity by suppressing IL-17 induction while enhancing IFN-γ production through the TLR4 pathway.

In a tumor-based mouse model, *Spirulina* LPS treatment enhanced serum levels of IFN-γ at early stages of tumor development and decreased serum IL-17 and IL-23 levels at later stages ([Fig. 3](#f3-or-37-02-0684){ref-type="fig"}). *Spirulina* LPS also induced IL-12 production in a CD4 T cell-dependent manner, probably through CD4 T cell-APC interaction ([Fig. 5C and D](#f5-or-37-02-0684){ref-type="fig"}), and induced IFN-γ production primarily by CD4 T cells. Based on previous reports on the inhibition of Th17 differentiation by IFN-γ ([@b32-or-37-02-0684],[@b33-or-37-02-0684]), these results can be interpreted as follows: *Spirulina* LPS facilitates the differentiation of tumor-primed CD4 T cells to Th1 cells. Subsequently, Th1-derived IFN-γ prevents Th17 differentiation and promotes CD8 T-cell activation. In addition, *Spirulina* LPS might also suppress IL-17 production through IFN-γ-independent pathways as shown in our *in vitro* experiments ([Fig. 4A](#f4-or-37-02-0684){ref-type="fig"}).

Alternatively, it is possible that although IL-17 elevation during tumor progression could prevent the generation of IFN-γ-producing T cells, *Spirulina* LPS might restore the generation of Th1 cells by reducing IL-17 production ([Fig. 3](#f3-or-37-02-0684){ref-type="fig"}). Recent experiments have revealed IL-17-mediated inhibition of Th1 differentiation ([@b35-or-37-02-0684]). It is also conceivable that *Spirulina* LPS inhibits tumor growth by reducing IL-17-induced angiogenesis, as previously reported ([@b11-or-37-02-0684]--[@b13-or-37-02-0684],[@b36-or-37-02-0684]). Of note, administration of anti-IL-17 mAb into tumor-bearing mice induced marked tumor regression accompanying IFN-γ production ([Fig. 4C and D](#f4-or-37-02-0684){ref-type="fig"}), consistent with a recent report showing tumor growth inhibition by IL-17 neutralization ([@b15-or-37-02-0684]). Regardless of the pathway, *Spirulina* LPS inhibits tumor growth by skewing the balance between IFN-γ and IL-17 responses toward IFN-γ production.

In this study, *Spirulina* LPS was shown to inhibit the *in vitro* generation of IL-17-producing cells through its action on APCs in a TLR4-dependent manner ([Fig. 4A and B](#f4-or-37-02-0684){ref-type="fig"}). There are reports demonstrating that CD86, but not CD80, on APCs plays an important role in the regulation of IL-17 production by T cells ([@b37-or-37-02-0684]), and that IL-27 produced by Mϕ/DC negatively regulates the development of Th17 cells ([@b38-or-37-02-0684]). Thus, *Spirulina* LPS-mediated TLR4 signaling may induce a change in APC status by modulating the expression patterns of co-stimulatory molecules and cytokines, leading to the attenuation of Th17 cell development. However, the precise mechanisms by which *Spirulina* LPS suppresses IL-17 and IL-23 remain to be elucidated.

In contrast to the tumor-promoting effects of the IL-17/IL-23 signaling axis, demonstrated in IL-17- or IL-23-deficient mice, several groups have described that Th17 cells or IL-17 promote tumor inhibition by increasing the generation of tumor-specific cytotoxic CD8 T cells ([@b39-or-37-02-0684],[@b40-or-37-02-0684]). Thus, whether Th17 cells or IL-17 induce tumor progression or antitumor immunity might be dependent on the varied main effector cells in the distinct tumor-host relationship ([@b41-or-37-02-0684]). Namely, Th17 cells/IL-17 could activate CD8 T cells, while inhibiting Th1 type of CD4 T cells. Otherwise, the strength of tumor immunogenicity or frequency of tumor-specific effector T cells might cause a discrepancy in the function of Th17 cells/IL-17, because adoptive transfer of tumor-reactive Th17 cells obtained from TCR transgenic mice or from *in vitro* stimulation with tumor inhibits tumor development ([@b39-or-37-02-0684],[@b40-or-37-02-0684]). In either case, IL-17-induced angiogenesis seems to be required to some extent for effector T cells to migrate into tumor tissue. Even in an IL-17-deficient host, IL-17 secreted by tumor cells may contribute to T-cell infiltration. Despite these possible explanations, the paradox in the function of Th17 cells/IL-17 is still unresolved.

IL-17 is also produced by certain tumors and IL-17 receptors have been detected in virtually all cells ([@b12-or-37-02-0684]). It has been reported that IL-17 stimulates tumor cells to proliferate and upregulates the expression of various cytokines, chemokines, and their receptors, leading to angiogenesis ([@b16-or-37-02-0684],[@b42-or-37-02-0684]--[@b44-or-37-02-0684]). However, we did not detect expression of IL-17 and IL-17 receptor in MH134 tumor cells (data not shown), indicating the importance of IL-17 responses in host-derived cells in MH134 tumor growth. Moreover, although TLR4 was expressed on MH134 tumor cells, *E. coli* and *Spirulina* LPS had virtually no effect on the *in vitro* growth of tumor cells (data not shown). Interestingly, we found that MH134 tumor cells expressed IFN-γ receptors and that cellular *in vitro* growth was inhibited by exogenous addition of IFN-γ (data not shown). Thus, *in vivo* induction of IFN-γ by *E. coli* and *Spirulina* LPS may partly contribute to the antitumor effects by virtue of the IFN-γ direct action on the tumor.

*E. coli* LPS induced antitumor effects against a primary tumor, but failed to enhance secondary immune responses in the same tumor after reimplantation ([Fig. 2A](#f2-or-37-02-0684){ref-type="fig"}). *E. coli* LPS induced high levels of IL-6 and IL-23, favoring the development of Th17 cells, and it considerably activated NK function ([Fig. 2B](#f2-or-37-02-0684){ref-type="fig"}). Thus, it is conceivable that *E. coli* LPS inhibits primary tumor growth via activation of NK cells, but prevents the generation of T cell-mediated antitumor immunity through IL-17 induction.

The effects of *E. coli* and *Spirulina* LPS involve TLR4 pathways, but *Spirulina* LPS was different from *E. coli* LPS in terms of cytokine induction. The structure of LPS of all gram-negative bacteria consists of a polysaccharide attached to a lipid component, lipid A, which is assumed to be responsible for the induction of cytokines. Although lipid A molecules from different bacteria were initially thought to be similar, recent evidence suggests structural and functional differences among LPS from different species ([@b25-or-37-02-0684],[@b45-or-37-02-0684]). Differences in the three-dimensional conformation of lipid A have been proposed to determine the strength of fitness to TLR4-CD14-MD2 complex, leading to the activation of intracellular signaling for cytokines ([@b46-or-37-02-0684],[@b47-or-37-02-0684]). LPS fractions from *E. coli* and *Salmonella* spp. are more potent cytokine inducers than those from *Bordetella pertussis* and *Bacteroides fragilis* ([@b48-or-37-02-0684],[@b49-or-37-02-0684]), while lipid A analog and LPS from *Rhodobacter* spp. have antagonistic properties against cytokine stimulation ([@b47-or-37-02-0684],[@b50-or-37-02-0684]). Although the structure of *Spirulina* LPS remains to be analyzed, the molecular conformation of *E. coli* LPS seems to be different from that of *Spirulina* LPS based on its ability to downregulate IL-17 with minimum induction of IL-6 and IL-23. Moreover, *Spirulina* LPS failed to induce endotoxin shock in contrast to *E. coli* LPS (20% and 100% survival in mice given 25 µg of *E. coli* and *Spirulina* LPS, respectively, 36 h after administration).

Experiments using different *Spirulina* preparations free of LPS have demonstrated antitumor activity. A calcium-chelating, sulfated polysaccharide from *S. platensis* suppressed metastasis of murine melanoma ([@b51-or-37-02-0684]). Oral administration of hot water extract of *Spirulina* is reported to suppress tumor growth through IFN-γ-mediated activation of NK cells but not CD8 T cells ([@b52-or-37-02-0684]). However, it was not clear whether IL-17 and IL-23 production were involved in the experimental system of that specific study. In contrast to those *Spirulina* preparations, we used a *Spirulina* LPS fraction extracted with phenol-water. Differences in the components of the *Spirulina* extracts may cause distinct bioactivities.

In conclusion, *Spirulina* LPS suppressed tumor growth by downregulating serum IL-17/IL-23 with concomitant induction of IFN-γ through TLR4. Furthermore, *Spirulina* LPS showed limited or no induction of IL-6 and IL-23 and altered the cytokine milieu in the tumor-bearing host from the Th17 to the Th1 type. Thus, we confirmed the importance of a balance between IFN-γ and IL-17/IL-23 levels in the regulation of tumor growth. It is noteworthy that *Spirulina* LPS was able to suppress spontaneous development of mammary tumors. Our results provide novel insights into the exploitation of TLR-based immunomodulators for cancer immunotherapy.
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![T cell-mediated suppression of tumor growth by *Spirulina* LPS through TLR4. (A) MH134 tumor cells were injected i.d. into C3H/HeN and C3H/HeJ mice on day 0. *Spirulina* LPS, *E. coli* LPS, or saline was injected i.p. on days 6, 13, and 20. Data represent mean ± standard error (SE) of 5 mice per group. \*P\<0.05 compared with saline. (B) The tumor-bearing C3H/HeN mice were treated with anti-CD4 and/or anti-CD8 or control rat IgG antibodies on days −1, 0, and 3, followed by saline or *Spirulina* LPS (100 µg) i.p. injection on days 8, 13, and 20. Data represent mean ± SE of 5 mice per group. \*P\<0.05 compared with saline. (C) MH134 tumors were taken from C3H/HeN mice treated with saline or *Spirulina* LPS (20 µg) 22 days after tumor implantation and tumor sections were stained with anti-CD4 or anti-CD8 antibody. Arrows show CD4 T or CD8 T lymphocytes (brown). Bar: 50 µm.](OR-37-02-0684-g00){#f1-or-37-02-0684}

![*Spirulina* LPS is incapable of activating NK cells but elicits immunity against reimplanted tumors. (A) MH134 tumors from *E. coli* or *Spirulina* LPS-treated C3H/HeN mice were surgically removed on day 22, and rechallenged with MH134 tumors on day 27. Tumor growth was measured. Data represent mean ± SE of 3--5 mice per group. \*P\<0.05 compared with saline. (B) Freshly prepared spleen cells from C3H/HeN or C3H/HeJ mice treated with PBS, *E. coli*, or *Spirulina* LPS were co-cultured with ^51^Cr-labeled YAC-1 or MH134 cells. The cytolytic activity of NK cells against YAC-1 or MH134 target cells was assessed in a chromium release assay. \*P\<0.05 compared with PBS.](OR-37-02-0684-g01){#f2-or-37-02-0684}

![Administration of *Spirulina* LPS to tumor-bearing mice decreases serum IL-17 and IL-23 levels, while increasing IFN-γ levels through the TLR4 pathway. (A-C) Serum cytokine levels were measured in tumor-bearing C3H/HeN or C3H/HeJ mice treated with LPS as in [Fig. 1A](#f1-or-37-02-0684){ref-type="fig"}. Data represent mean ± SE of 5 mice per group. \*P\<0.05 compared with saline. (D) Tumor-bearing C3H/HeN mice were treated with anti-CD4 and/or anti-CD8, or rat IgG antibodies (on days −1, 0, and 3) and *Spirulina* LPS (on days 8, 13, and 20), and serum IFN-γ levels were measured 14 days after tumor implantation *(in vivo)*. Data represent mean ± SE of 5 mice per group. \*P\<0.05 compared with rat IgG. Spleen cells from MH134 tumor-bearing C3H/HeN mice treated with *E. coli* or *Spirulina* LPS were prepared on day 22 and cultured without exogenous addition of tumor cells for 4 days. The culture supernatant was assessed for IFN-γ *(in vitro)*. \*P\<0.05 compared with saline.](OR-37-02-0684-g02){#f3-or-37-02-0684}

![*Spirulina* LPS inhibits IL-17 production through TLR4 on APCs, and neutralization of endogenous IL-17 in MH134-bearing mice results in tumor regression. (A) Spleen cells from OVA-specific TCR transgenic mice were cultured with OVA in the absence (left) or presence (right) of anti-IFN-γ mAb for 5 days. Graded doses of *E. coli* or *Spirulina* LPS were further added into the culture to examine their effect on IL-17 production. Background IL-17 production without OVA was \<22 pg/ml. \*P\<0.05 compared with control. (B) CD4 T cells from OVA-primed C3H/HeJ mice and splenic APCs from C3H/HeN or C3H/HeJ mice were co-cultured with OVA in the absence or presence of *Spirulina* LPS for 5 days. The culture supernatant levels of IL-17 were measured. \*P\<0.05 compared with no *Spirulina* LPS. (C) Tumor-bearing C3H/HeN mice were injected with anti-IL-17, anti-IFN-γ, or control rat IgG antibodies 1 day before and 4 days after tumor implantation. Data represent mean tumor growth ± SE of 5 mice per group. \*P\<0.05 compared with no Ab. (D) In the same experiment as in C, serum IFN-γ was measured *(in vivo)*. \*P\<0.05 compared with Rat IgG. Spleen cells from tumor-bearing mice treated with anti-IL-17 mAb or Rat IgG as in C were prepared 24 days after tumor implantation and cultured for 4 days to measure the production of IFN-γ (*in vitro*). Data represent mean ± SE. \*P\<0.05 compared with Rat IgG.](OR-37-02-0684-g03){#f4-or-37-02-0684}

![*Spirulina* LPS induces limited or does not induce the production of IL-6 and IL-23 *in vivo*, but augments T cell-dependent IL-12 induction. (A) C3H/HeN and C3H/HeJ mice were injected i.p. with *E. coli* LPS or *Spirulina* LPS (200 µg). Serum IL-6, TGF-β, or IL-23 levels were assessed 4 h later. Data represent mean ± SE of 4--5 mice per group. \*P\<0.05 compared with prior to injection (pre). (B) Whole spleen cells from DO11.10 mice were cultured in the presence of *E. coli* or *Spirulina* LPS without OVA for 5 days and B-cell proliferation was estimated. \*P\<0.05 compared with no LPS. (C) Serum IL-12 levels were measured in tumor-bearing C3H/HeN or C3H/HeJ mice treated as in [Fig. 1A](#f1-or-37-02-0684){ref-type="fig"}. Data represent mean ± SE of 5 mice per group. \*P\<0.05 compared with saline. (D) Tumor-bearing C3H/HeN mice were treated with *Spirulina* LPS and with anti-CD4 and/or anti-CD8, or rat IgG antibodies as in [Fig. 1B](#f1-or-37-02-0684){ref-type="fig"}. Serum levels of IL-12 were measured on day 14. \*P\<0.05 compared with saline.](OR-37-02-0684-g04){#f5-or-37-02-0684}

![*Spirulina* LPS suppresses the spontaneous development of mammary tumors. HER-2/*neu* transgenic mice were injected i.p. with *Spirulina* LPS (80 µg) or PBS every week between 120 and 240 days after birth. A palpable node over 5×5 mm was considered a tumor. Data represent mean ± SE of 8 mice per group. (A) Tumor incidence and (B) tumor size, expressed as summation of tumor area (width × length in mm^2^) of palpable nodes per mouse are depicted. \*P\<0.05 compared with PBS by Fischer\'s exact test (A), and Mann-Whitney U test (B).](OR-37-02-0684-g05){#f6-or-37-02-0684}
